Back to Awarded Treatment Trials
Awarded Trial: 04T-584
Schizophrenia with Metabolic Abnormalities
Secondary Drug Intervention
Duration of Study Period for Each Subject
Body mass index and related measures; glucose, lipids and related measures; PANSS, CGI, cognitive battery
Fifty-four (54) patients with schizophrenia were randomized to adjunct pioglitazone or placebo for 12 weeks. The study was done at five sites in the U.S. and one in China. Patients on pioglitazone showed a significant improvement on the PANSS total score as well as improvement in some metabolic indicators, as expected. Pioglitzaone had no effect on cognition. Analysis of the data was complicated by the fact that results in the Chinese population differed somewhat that at the five U.S. sites.
Smith RC, Jin H, Li C, Bark N, Shekhar A, Dwivedi S, et al. Effects of Pioglitazone on Metabolic Abnormalities, Psychopathology, and Cognitive Function in Schizophrenic Patients Treated with Antipsychotic Medication: A Randomized Double-Blind Study. Shizophr Res 2013;143:18-24.
Department of Psychiatry
NYU Medical School
P.O. Box 316
City or Town
State or Province
Zip or Postal Code